Latest Breaking News On - Arena pharmaceuticals - Page 3 : comparemela.com

DelveInsight Business Research, LLP: Global Infection Prevention and Control Market is Likely to Increase at a Steady Growth Rate of ~6% by 2030

The surge in the infection prevention and control demand market is due to factors such as the rising occurrence of chronic diseases, escalating rates of surgical procedures necessitating stringent

United statesAkeso biopharmaTheravance biopharmaEli lillyHutchison medipharmaCinrx pharmaShruti thakurNanosonics auditproRedhill biopharmaPrnewswire delveinsightLandos biopharmaIltoo pharmaDraconis pharmaBristol myers squibbMatachana groupMarket research

Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs (NYSE:PFE)

Pfizer shares lagged behind pharma rally due to inflated expectations, one-time losses, write-offs, and the Seagen acquisition. Find out why PFE stock is a Buy.

United statesAlexandros michailidisAbrysvo rsvpreAdbry adtralzaVyndaqel vyndamaxBristol myers squibbBristol myersVelsipity etrasimodAlbert bourlaWavelength researchUs centers for diseaseWavelength research dataConnecticut department of public healthArena pharmaceuticalsSeeking alphaStock editorial

Anavex Life Sciences Announces Expansion of Leadership Team - Anavex Life Sciences (NASDAQ:AVXL)

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of

United statesJeffrey edwardsChristopheru misslingTerrie kellmeyerJuan carlos lopez talaveraMichael houghtonAndrewj barwickiClinical developmentClinical development at acer therapeuticsRegulatory affairsUniversity of pittsburgh medical centerAmylin pharmaceuticalsMichaelj fox foundation for parkinson researchRochester institute of technologyUniversity of rochesterEuropean medicines agency

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals (NASDAQ:CRBP), AbbVie (NYSE:ABBV)

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals (NASDAQ:CRBP), AbbVie (NYSE:ABBV)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesNew yorkTroy binghamAmyris incIntec pharma ltdAbbvie incZynerba pharmaceuticals incCorbus pharmaceuticals holdings incArena pharmaceuticalsCardiol therapeutics incPfizer incJazz pharmaceuticalsjazz acquired gw pharmaceuticalsBenzinga cannabis capital conferenceOpportunities aheadPharmaceuticals holdings

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio.

United statesStanford universityLos angelesAgnieszka czechowiczDonaldb kohnGaurav shahCompany cranburyStanford university school of medicineAmerican society of geneDrug administrationRocket pharmaceuticalsDepartment of pediatricsRocket pharmaceuticals incTreatment centerAlexion pharmaceuticalsDivision of hematology oncology